Zogenix (NASDAQ: ZGNX) was featured in a recent U.S. Equity Research Report published by Mizuho Securities USA LLC. The report reads, “We hosted a doc call last week with Dr. Kathryn Davis from UPenn Epilepsy Center to discuss Zogenix’s recent Lennox Gastaut (LGS) Phase 3 data. While the data looks underwhelming compared to Epidiolex on the surface, we believe FINTEPLA may ultimately have an edge in terms of durability, especially against Epidiolex where the dropout rate appears to be high. Dr. Davis estimates that she will try FINTEPLA for ~30% of her LGS patients. At the current price, we believe investors assign minimal credit to the LGS indication and we continue to see upside in the shares.”
To request access to the full report, visit http://nnw.fm/SaZ9d
About Zogenix
Zogenix, Inc. is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA(R) (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency. For more information, visit the company’s website at www.Zogenix.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork.